<Record>
<Term>Copper Cu 64 Trastuzumab</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Radioimmunoconjugate</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Radiopharmaceutical Compound/Radioimmunoconjugate/Copper Cu 64 Trastuzumab</ClassificationPath>
<BroaderTerm>Radioimmunoconjugate</BroaderTerm>
<BroaderTerm>Radiopharmaceutical Compound</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Copper Cu 64 Trastuzumab</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>Copper Cu 64 Trastuzumab</Synonym>
<Synonym>Cu-64-trastuzumab</Synonym>
<Description>A diagnostic radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody trastuzumab conjugated with the positron-emitting radioisotope copper Cu 64. Copper Cu 64 trastuzumab binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2), allowing the detection of HER2 distribution using positron emission tomography (PET).</Description>
<Source>NCI Thesaurus</Source>
</Record>
